{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-115782","form_type":"8-K","ticker":null,"cik":"0001270073","company_name":"INTERCEPT PHARMACEUTICALS, INC.","filed_at":"2023-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.490679+00:00","generated_at":"2026-06-08T08:45:59.111506+00:00","sec_items":["1.01","2.01","3.01","2.04","3.03","5.01","5.03","5.02","8.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":1.0,"calibrated_materiality_score":1.0,"confidence":"high","headline":"Alfasigma completes acquisition of Intercept Pharmaceuticals for $19.00 per share","bullets":["Tender offer closed with 74.5% of shares tendered; merger consummated under Section 251(h) without stockholder vote.","Shares delisted from Nasdaq; Company will file Form 15 to suspend SEC reporting obligations.","Board replaced by Alfasigma appointees: Francesco Balestrieri, Stefano Pasi, Michele Cera; Jerome Durso remains CEO, Balestrieri appointed President.","2.00% Convertible Senior Notes and 3.50% Convertible Senior Secured Notes now convertible into cash at $19.00 per share; holders have repurchase rights.","Certificate of incorporation and bylaws amended and restated as of the merger effective time."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-115782","json":"https://secwatch.observer/filing/0001104659-23-115782.json","markdown":"https://secwatch.observer/filing/0001104659-23-115782.md","text":"https://secwatch.observer/filing/0001104659-23-115782.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1270073/000110465923115782/0001104659-23-115782-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1270073/000110465923115782/tm2330108d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T08:45:59.111506+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"00dba75242","claim":"Francesco Balestrieri was appointed as Director at INTERCEPT PHARMACEUTICALS, INC..","evidence_excerpt":"The directors of Purchaser immediately prior to the Effective Time were Francesco Balestrieri, Stefano Pasi and Michele Cera.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465923115782/0001104659-23-115782-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"12be9b10ec","claim":"Jerome Durso resigned as Director at INTERCEPT PHARMACEUTICALS, INC..","evidence_excerpt":"Jerome Durso, Paolo Fundarò, Mark Pruzanski, M.D., Srinivas Akkaraju, M.D., Ph.D., Luca Benatti, Ph.D., Daniel Bradbury, Keith Gottesdiener, M.D., Nancy Miller-Rich, Dagmar Rosa-Bjorkeson, Gino Santini and Glenn Sblendorio each resigned and ceased to be directors","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465923115782/0001104659-23-115782-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"3572f4f121","claim":"Glenn Sblendorio resigned as Director at INTERCEPT PHARMACEUTICALS, INC..","evidence_excerpt":"Jerome Durso, Paolo Fundarò, Mark Pruzanski, M.D., Srinivas Akkaraju, M.D., Ph.D., Luca Benatti, Ph.D., Daniel Bradbury, Keith Gottesdiener, M.D., Nancy Miller-Rich, Dagmar Rosa-Bjorkeson, Gino Santini and Glenn Sblendorio each resigned and ceased to be directors","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465923115782/0001104659-23-115782-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"399fb063a3","claim":"Nancy Miller-Rich resigned as Director at INTERCEPT PHARMACEUTICALS, INC..","evidence_excerpt":"Jerome Durso, Paolo Fundarò, Mark Pruzanski, M.D., Srinivas Akkaraju, M.D., Ph.D., Luca Benatti, Ph.D., Daniel Bradbury, Keith Gottesdiener, M.D., Nancy Miller-Rich, Dagmar Rosa-Bjorkeson, Gino Santini and Glenn Sblendorio each resigned and ceased to be directors","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465923115782/0001104659-23-115782-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"5d29e7f05f","claim":"Daniel Bradbury resigned as Director at INTERCEPT PHARMACEUTICALS, INC..","evidence_excerpt":"Jerome Durso, Paolo Fundarò, Mark Pruzanski, M.D., Srinivas Akkaraju, M.D., Ph.D., Luca Benatti, Ph.D., Daniel Bradbury, Keith Gottesdiener, M.D., Nancy Miller-Rich, Dagmar Rosa-Bjorkeson, Gino Santini and Glenn Sblendorio each resigned and ceased to be directors","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465923115782/0001104659-23-115782-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"7021057dbf","claim":"Keith Gottesdiener resigned as Director at INTERCEPT PHARMACEUTICALS, INC..","evidence_excerpt":"Jerome Durso, Paolo Fundarò, Mark Pruzanski, M.D., Srinivas Akkaraju, M.D., Ph.D., Luca Benatti, Ph.D., Daniel Bradbury, Keith Gottesdiener, M.D., Nancy Miller-Rich, Dagmar Rosa-Bjorkeson, Gino Santini and Glenn Sblendorio each resigned and ceased to be directors","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465923115782/0001104659-23-115782-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"9127656748","claim":"Luca Benatti resigned as Director at INTERCEPT PHARMACEUTICALS, INC..","evidence_excerpt":"Jerome Durso, Paolo Fundarò, Mark Pruzanski, M.D., Srinivas Akkaraju, M.D., Ph.D., Luca Benatti, Ph.D., Daniel Bradbury, Keith Gottesdiener, M.D., Nancy Miller-Rich, Dagmar Rosa-Bjorkeson, Gino Santini and Glenn Sblendorio each resigned and ceased to be directors","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465923115782/0001104659-23-115782-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"930f0edf0f","claim":"Paolo Fundarò resigned as Director at INTERCEPT PHARMACEUTICALS, INC..","evidence_excerpt":"Jerome Durso, Paolo Fundarò, Mark Pruzanski, M.D., Srinivas Akkaraju, M.D., Ph.D., Luca Benatti, Ph.D., Daniel Bradbury, Keith Gottesdiener, M.D., Nancy Miller-Rich, Dagmar Rosa-Bjorkeson, Gino Santini and Glenn Sblendorio each resigned and ceased to be directors","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465923115782/0001104659-23-115782-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"98d2949d74","claim":"Mark Pruzanski resigned as Director at INTERCEPT PHARMACEUTICALS, INC..","evidence_excerpt":"Jerome Durso, Paolo Fundarò, Mark Pruzanski, M.D., Srinivas Akkaraju, M.D., Ph.D., Luca Benatti, Ph.D., Daniel Bradbury, Keith Gottesdiener, M.D., Nancy Miller-Rich, Dagmar Rosa-Bjorkeson, Gino Santini and Glenn Sblendorio each resigned and ceased to be directors","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465923115782/0001104659-23-115782-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"a9174e1b80","claim":"Michele Cera was appointed as Director at INTERCEPT PHARMACEUTICALS, INC..","evidence_excerpt":"The directors of Purchaser immediately prior to the Effective Time were Francesco Balestrieri, Stefano Pasi and Michele Cera.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465923115782/0001104659-23-115782-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"b2464af0f3","claim":"Gino Santini resigned as Director at INTERCEPT PHARMACEUTICALS, INC..","evidence_excerpt":"Jerome Durso, Paolo Fundarò, Mark Pruzanski, M.D., Srinivas Akkaraju, M.D., Ph.D., Luca Benatti, Ph.D., Daniel Bradbury, Keith Gottesdiener, M.D., Nancy Miller-Rich, Dagmar Rosa-Bjorkeson, Gino Santini and Glenn Sblendorio each resigned and ceased to be directors","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465923115782/0001104659-23-115782-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"b7cbc0e6e5","claim":"Srinivas Akkaraju resigned as Director at INTERCEPT PHARMACEUTICALS, INC..","evidence_excerpt":"Jerome Durso, Paolo Fundarò, Mark Pruzanski, M.D., Srinivas Akkaraju, M.D., Ph.D., Luca Benatti, Ph.D., Daniel Bradbury, Keith Gottesdiener, M.D., Nancy Miller-Rich, Dagmar Rosa-Bjorkeson, Gino Santini and Glenn Sblendorio each resigned and ceased to be directors","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465923115782/0001104659-23-115782-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"dad5c34c35","claim":"Francesco Balestrieri was appointed as President at INTERCEPT PHARMACEUTICALS, INC..","evidence_excerpt":"Mr. Durso was removed as the President and Mr. Balestrieri was appointed as the President of the Surviving Corporation.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465923115782/0001104659-23-115782-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President"}],"fact_type":"executive_change"},{"claim_id":"e93fb480c5","claim":"Jerome Durso was removed as President at INTERCEPT PHARMACEUTICALS, INC..","evidence_excerpt":"Mr. Durso was removed as the President and Mr. Balestrieri was appointed as the President of the Surviving Corporation.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465923115782/0001104659-23-115782-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"removed"},{"label":"Role","value":"President"}],"fact_type":"executive_change"},{"claim_id":"f17784c08d","claim":"Stefano Pasi was appointed as Director at INTERCEPT PHARMACEUTICALS, INC..","evidence_excerpt":"The directors of Purchaser immediately prior to the Effective Time were Francesco Balestrieri, Stefano Pasi and Michele Cera.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465923115782/0001104659-23-115782-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"f4ec9da3ed","claim":"Dagmar Rosa-Bjorkeson resigned as Director at INTERCEPT PHARMACEUTICALS, INC..","evidence_excerpt":"Jerome Durso, Paolo Fundarò, Mark Pruzanski, M.D., Srinivas Akkaraju, M.D., Ph.D., Luca Benatti, Ph.D., Daniel Bradbury, Keith Gottesdiener, M.D., Nancy Miller-Rich, Dagmar Rosa-Bjorkeson, Gino Santini and Glenn Sblendorio each resigned and ceased to be directors","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465923115782/0001104659-23-115782-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"45e9ab7efb142a6bb0472b0ed5fbeabebdf9af9a","claim":"INTERCEPT PHARMACEUTICALS, INC.: Bylaws amended and restated in their entirety at the Effective Time pursuant to the merger agreement.","evidence_excerpt":"Pursuant to the terms of the Merger Agreement, at the Effective Time, the Company’s bylaws, as in effect immediately prior to the Effective Time, were amended and restated in their entirety (the “Second Amended and Restated Bylaws”).","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465923115782/0001104659-23-115782-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"}],"fact_type":"governance_change"},{"claim_id":"6708097014ac9db9709fd303341cd0531a10c8b6","claim":"INTERCEPT PHARMACEUTICALS, INC.: Certificate of incorporation amended and restated in its entirety at the Effective Time pursuant to the merger agreement.","evidence_excerpt":"Pursuant to the terms of the Merger Agreement, as of the Effective Time, the Company’s certificate of incorporation, as in effect immediately prior to the Effective Time, was amended and restated in its entirety (the “Amended and Restated Certificate of Incorporation”).","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465923115782/0001104659-23-115782-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"}],"fact_type":"governance_change"},{"claim_id":"0c64b12cac8ae125dacf9603225813f3461ec1c8","claim":"INTERCEPT PHARMACEUTICALS, INC. underwent a change of control involving Alfasigma S.p.A. for $19.00 per Share in cash (closed 2023-11-08).","evidence_excerpt":"Purchaser commenced a tender offer (the “Offer”) on October 11, 2023, to acquire all of the outstanding shares of the Company’s common stock (the “Shares”) at an offer price of $19.00 per Share, net to the seller in cash, without interest (the “Offer Price”), subject to any applicable withholding taxes. The Offer and related withdrawal rights expired as","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465923115782/0001104659-23-115782-index.htm","confidence":0.95,"family_label":"M&A Transactions","details":[{"label":"Action","value":"change of control"},{"label":"Counterparty","value":"Alfasigma S.p.A."},{"label":"Consideration","value":"$19.00 per Share in cash"},{"label":"Closing","value":"2023-11-08"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}